There are currently 124 active clinical trials seeking participants for Pancreatic Cancer research studies. The states with the highest number of trials for Pancreatic Cancer participants are California, New York, Illinois and Texas.
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
NCT03190941
Recruiting
Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cells. Objective: To see if anti-KRAS G12 V mTCR cells are safe and can shrink tumors. Eligibility: Adults at least 18 years old with cancer that has the KRAS G12V molecule on the surface of tumors. Design: In another protocol, participants will: Be screene... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
03/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer, Rectal Cancer
Register for Updates
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT03454035
Recruiting
This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/14/2025
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Tumor, Solid, Pancreatic Cancer, Melanoma
Register for Updates
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT06440005
Recruiting
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Sarah Cannon Research Center, Nashville, Tennessee +1 locations
Conditions: Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Angiosarcoma, Solid Tumor
Register for Updates
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT06122896
Recruiting
The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasm
Register for Updates
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
NCT05975593
Recruiting
This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Locally Advanced Cervical Carcinoma, Locally Advanced Cervical Cancer, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer, Cervical Cancer, Pancreas Cancer, Pancreatic Cancer, Cancer of the Cervix, Cancer of the Pancreas
Register for Updates
Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
NCT05535894
Recruiting
This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Shailendra Singh, Morgantown, West Virginia
Conditions: Pancreatic Cancer
Register for Updates
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
NCT04543071
Recruiting
The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. The treatment consists of standard chemotherapy (gemcitabine and nab-paclitaxel) which is FDA approved and is standard treatment for patients with pancreatic adenocarcinoma. Participants will receive immunotherapy (cemiplimab) which activates the body's immune... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Columbia University Irving Medical Center, New York, New York +1 locations
Conditions: Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
Register for Updates
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT04981119
Recruiting
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Banner Health, Gilbert, Arizona +12 locations
Conditions: Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Register for Updates
Using an End-of-life Conversation Game to Engage Patients with Cancer in Advance Care Planning: Phase 2
NCT06384417
Recruiting
The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with various solid cancer types (including: breast, gastro-intestinal, lung, melanoma, head and neck, and/or genito-urinary cancers) treated at Penn State Health clinics and their loved ones perform advance care planning (ACP). The main questions it aims to answer are: What modifications and/or adaptations are necessary to Hello for u... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Penn State Cancer Institute, Hershey, Pennsylvania
Conditions: Breast Cancer, Lung Cancer, Genito-Urinary Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Liver Cancer, Head and Neck Cancer, Melanoma
Register for Updates
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients with Pancreatic Cancer
NCT05086250
Recruiting
This is a prospective, single center, double blind, randomized, crossover feasibility study of oral ketamine versus placebo for the treatment of anxiety in patients with pancreatic cancer currently receiving or within 12 weeks of receiving cancer targeted therapy. The primary objective is to determine the feasibility of enrolling subjects and treatment adherence. The secondary objectives are to describe the safety and tolerability. Exploratory objectives are to assess the effect of ketamine/plac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Anxiety, Pancreatic Cancer
Register for Updates
Lidocaine Infusion in Pancreatic Cancer
NCT04048278
Recruiting
This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will be used for the proposed study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: University of Illnois at Chicago, Chicago, Illinois
Conditions: Pancreatic Cancer
Register for Updates
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
NCT02674100
Recruiting
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama +15 locations
Conditions: Pancreatic Cancer
Register for Updates